Please assess the completion status of the following clinical trial:

Trial Title: Qvar Versus Clenil, a General Practice Research Database Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged: 4-80 years~* Paediatric cohort (aged 4-11 years), and~* Adult cohort (aged 12-80 years )~* Evidence of asthma and current asthma therapy:~* All cohorts (IPDI, IPDS, IPDA):~  * a diagnostic code for asthma, and / or \*≥2 prescriptions for asthma at different points in time during the prior year and/or IPDI only: ≥2 prescriptions for asthma therapies during the outcome year, including ≥1 ICS prescription in addition to that received at IPD~IPDA and IPDS only:~* 1 ICS prescription in the baseline year, and~* 1 other asthma prescription during the baseline year.~  \*Evidence of current therapy:~* 2 prescription for ICS during the outcome year (i.e. ≥1 prescription in addition to the prescription at index date~  * Have at least one year of up-to-standard (UTS) baseline data (prior to the IPD) and at least one year of UTS outcome data (following the IPD).~Exclusion Criteria:~* Had a COPD read code at any time; and/or~* Had any chronic respiratory disease, except asthma, at any time; and/or~* Patients on maintenance oral steroids during baseline year~* Received a combination inhaler in addition to a separate ICS inhaler in the baseline year; and/or~* Received ICS therapy during baseline year via DPI (IPDA and IPDS cohorts only).~* If they received multiple ICS prescriptions on the same day at IPD or immediately before

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IPDI EF HFA-BDP (Type: None): Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
- IPDI SP HFA-BDP (Type: None): Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
- IPDA SP HFA-BDP (Type: None): Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
- IPDA EF HFA-BDP (Type: None): Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
- IPDS SP HFA-BDP (Type: None): Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
- IPDS EF HFA-BDP (Type: None): Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date

Based on this trial design, predict the completion outcome and termination type (if applicable).